Page last updated: 2024-08-23

cabergoline and Acromegaly

cabergoline has been researched along with Acromegaly in 84 studies

Research

Studies (84)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.19)	18.7374
1990's	9 (10.71)	18.2507
2000's	19 (22.62)	29.6817
2010's	45 (53.57)	24.3611
2020's	10 (11.90)	2.80

Authors

Authors	Studies
Arenas, C; Battellino, M; Caney, S; Corsini, A; Fleeman, LM; Fracassi, F; Leal, RO; Miceli, DD; Niessen, SJ; Sieber-Ruckstuhl, NS; Zeugswetter, FK	1
Aral, F; Bilgic, B; Gul, N; Hacisahinogullari, H; Selcukbiricik, OS; Tanakol, R; Uzum, AK; Yalin, GY	1
Amarù, J; Dogan, F; Feelders, RA; Ferone, D; Gatto, F; Hofland, LJ; Neggers, SJCMM; van der Lelij, AJ; van Koetsveld, PM	1
Fleseriu, M; Gadelha, M; Hanman, K; Haria, K; Houchard, A; Khawaja, S; Ribeiro-Oliveira, A; Zhang, Z	1
Ballarino, MC; Basavilbaso, NXG; Bruera, D; Bruno, OD; Chervin, AB; Danilowicz, K; Fainstein-Day, P; Fidalgo, SG; Frigeri, A; Glerean, M; Guelman, R; Guitelman, M; Isaac, G; Katz, DA; Knoblovits, P; Librandi, F; Mallea-Gil, MS; Manavela, M; Mereshian, P; Moncet, D; Montes, ML; Pignatta, A; Rogozinsky, A; Sago, LR; Servidio, M; Spezzi, M; Stalldecker, G; Tkatch, J; Vitale, NM	1
Colwell, HH; Fleseriu, M; Fogelfeld, L; Gordon, MB; Haviv, A; Ludlam, WH; Mathias, SD; Sisco, J	1
Araujo, B; da Costa Oliveira, M; de Azevedo Oliveira, B; Dos Santos, TM; Ferreira, NP; Ongaratti, BR; Pereira-Lima, JFS; Rech, CGSL	1
Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H	1
Kawakami, K; Matsubayashi, K	1
Knappe, UJ; Petroff, D; Quinkler, M; Schmid, SM; Schopohl, J; Tönjes, A	1
Giraldi, EA; Ioachimescu, AG	1
Abreu, C; Cadena-Obando, D; Cuevas-Ramos, D; Espinosa-de-Los-Monteros, AL; González-Virla, B; Ibarra-Salce, R; Mercado, M; Mercado-Cherem, A; Pérez-Reyes, SP; Portocarrero-Ortiz, LA; Sosa-Eroza, E; Talavera, JO; Vergara-López, A	1
Durcan, E; Fidan, MC; Kadioglu, P; Korkmaz, OP; Ozkaya, HM; Sahin, S	1
Agostini, H; Arnoux, A; Brailly-Tabard, S; Chanson, P; Kuhn, E; Massart, C; Mavromati, M; Piketty, ML; Souberbielle, JC; Young, J	1
Cha, HJ; Kim, JH; Kim, SW; Kim, YH; Lee, JH; Lee, SY; Paek, SH; Shin, CS	1
Bredella, MA; Dichtel, LE; Gerweck, AV; Miller, KK; Schorr, M; Swearingen, B; Woodmansee, WW; Young, BJ	1
Demidowich, AP; Hannah-Shmouni, F; Lodish, M; Rowell, J; Stratakis, CA	1
Ciresi, A; Giordano, C; Guarnotta, V; Radellini, S	1
Dalmolin, MD; Gadelha, MR; Kasuki, L; Wildemberg, LE	1
Akirov, A; Eizenberg, Y; Glaser, B; Greenman, Y; Mansiterski, Y; S'chigol, I; Shimon, I; Shraga-Slutzky, I	1
Akbari, H; Alaei-Shahmiri, F; Asadi, P; Ghorbani, M; Honardoost, M; Imani, M; Kaynama, MR; Khamseh, ME; Malek, M	1
Bolanowski, M; Hubalewska-Dydejczyk, A; Kos-Kudła, B; Lewiński, A; Ruchała, M; Zgliczyński, W	1
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W	1
Abucham, J; Boguszewski, CL; Bronstein, MD; Correa-Silva, SR; Czepielewski, MA; Duarte, FG; Gadelha, MR; Huayllas, MKP; Jallad, RS; Kasuki, L; Musolino, NR; Naves, LA; Ribeiro-Oliveira Junior, A; Soares, BS; Vilar, L	1
Fleseriu, M	1
Arnez, L; Biagetti, B; Dalama, B; Mesa, J; Obiols, G; Valladares, S	1
Góth, M	1
Abreu, A; Albarrán, AA; Carrasco, CA; Espinosa de los Monteros, AL; Gadelha, M; Mercado, M	1
Abucham, J; Boguszewski, C; Dias, M; Gadelha, M; Kasuki, L; Musolino, N; Vieira, JG	1
Gadelha, MR; Kasuki, L; Vieira Neto, L	1
Bernabeu, I; Marazuela, M; Ramos-Leví, A; Sampedro-Núñez, M	1
Figueroa-Núñez, C; González, E; Gutierrez, M; Hernán Martínez, J; Mangual-García, M; Mansilla-Letelier, P; Miranda, Mde L; Palermo-Garofalo, C; Sánchez, A; Santiago, M; Torres, O; Trinidad, R	1
Marek, J	1
Elenkova, A; Gerenova, J; Hristozov, K; Kalinov, K; Kamenov, Z; Kirilov, G; Marinov, M; Natchev, E; Orbetzova, M; Tcharaktchiev, D; Tsinlikov, I; Vandeva, S; Yaneva, M; Zacharieva, S	1
Chanson, P	1
Auriemma, RS; Colao, A; Ferreri, L; Pivonello, R; Priscitelli, P	1
Bronstein, MD; Fleseriu, M; Greenman, Y; Jallad, RS; Shimon, I; Yedinak, CG	1
Assayag, P; Bouchachi, A; Brailly-Tabard, S; Chanson, P; Kamenicky, P; Kuhn, E; Maione, L; Rozière, M; Salenave, S; Young, J	1
Broder, MS; Carmichael, JD; Chang, E; Ludlam, WH; Neary, MP	1
Bernabeu, I; Blanco, C; Casany, R; Cordido, F; Cuatrecasas, G; Fajardo, C; Gálvez, MÁ; Lucas, T; Maraver, S; Marazuela, M; Martín, T; Paja, M; Picó, A; Puig-Domingo, M; Resmini, E; Romero, E; Soto, A; Venegas, E; Vilchez, R	1
Fleseriu, M; Lim, DS	1
Abucham, J; Bronstein, MD; Casagrande, A; Jallad, RS; Mota, JI; Tabet, A	1
Chanson, P; Kuhn, E	1
Bolu, E; Kebapcilar, L; Kutlu, M; Sahin, M; Taslipinar, A; Uckaya, G	1
Drake, WM; Metcalfe, KA; Moyes, VJ	1
Chung, TT; Drake, WM; Higham, CE; Lawrance, J; Trainer, PJ	1
Albuquerque, LA; Almeida, JP; Ferraz, CL; Ferraz, TM; Gondim, J; Mota, I	1
Bronstein, MD; Jallad, RS	1
Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM	1
Bidlingmaier, M; Gutt, B; Roemmler, J; Schneider, HJ; Schopohl, J; Sievers, C; Steffin, B	1
Abucham, J; Alves Martins, MR; Mattar, P	1
Albuquerque, JL; Azevedo, MF; Casulari, LA; Faria, MS; Figueiredo, P; Montenegro, RM; Nascimento, GC; Naves, LA; Vilar, L	1
Cevik, C; Feray, H; Izgi, C; Mansuroglu, D; Nugent, K; Saltan, Y	1
Chanson, P; Maison, P; Sandret, L	1
Atkinson, AB; Aylwin, S; Bidlingmaier, M; Drake, WM; Higham, CE; Lewis, A; Martin, NM; Moyes, V; Newell-Price, J; Trainer, PJ	1
Alvarez-Escolá, C; Bernabeu, I; Cabezas-Agrícola, JM; Casanueva, FF; Lucas, T; Marazuela, M; Paniagua, AE; Pavón, I	1
Assayag, P; Bouchachi, A; Chanson, P; Garcia, C; Kallel, N; Maione, L; Maison, P; Salenave, S; Young, J	1
Bancroft, T; Burton, T; Le Nestour, E; Neary, M	1
Díez, JJ; Iglesias, P	1
Fukuoka, H; Iguchi, G; Inoshita, N; Nishizawa, H; Suda, K; Takahashi, M; Takahashi, Y; Yamada, S; Yamamoto, M	1
Ezzat, S	1
Attanasio, R; Cozzi, R; Lasio, G; Lodrini, S	1
Freda, PU; Khandji, AG; Nuruzzaman, AT; Post, KD; Reyes, CM; Sundeen, RE	1
Newell-Price, J; Ross, R; Selvarajah, D; Webster, J	1
Albertelli, M; Arvigo, M; Barreca, A; Culler, MD; Ferone, D; Jaquet, P; Minuto, F; Moreau, JP; Saveanu, A; Semino, C; Taylor, JE	1
Catargi, B; Gatta, B; Hau, DH; Roger, P; Tabarin, A	1
Cappabianca, P; Colao, A; Cozzi, R; Ghigo, E; Martino, E; Scanarini, M	1
Bianchi, F; Culler, MD; Dadati, P; Ferone, D; Jaquet, P; Minuto, F; Ravetti, JL; Rebora, A; Resmini, E; Saveanu, A; Spaziante, R; Zona, G	1
Abrams, PJ; Abs, R; Verhelst, JA	1
Ansorge, O; Fazal-Sanderson, V; Fernandez, A; Karavitaki, N; Wass, JA	1
Arvigo, M; Barreca, A; Cariola, G; Foppiani, L; Giordano, G; Minuto, F; Ponzani, P	1
Cerbone, G; Cirillo, S; Colao, A; Di Sarno, A; Ferone, D; Lombardi, G; Marzullo, P; Merola, B; Sarnacchiaro, F	1
Fowler, J; Howlett, TA; Jackson, SN	1
Arosio, M; Biella, O; Faglia, G; Gambino, G; Muratori, M; Romano, C	1
Abs, R; Beckers, A; Coolens, JL; Mahler, C; Maiter, D; Nobels, F; Van Acker, K; Verhelst, J	1
Baldelli, R; Bultrini, A; Caracciolo, B; Ferretti, E; Gulino, A; Jaffrain-Rea, ML; Minniti, G; Tamburrano, G	1
Colao, A; Lombardi, G	1
Attanasio, R; Barausse, M; Branca, V; Cozzi, R; Da Re, N; Dallabonzana, D; Gelli, D; Oppizzi, G; Orlandi, P	1
Colao, A; Di Somma, C; Ferone, D; Filippella, M; Lombardi, G; Marzullo, P; Pivonello, R	1
Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A	1
Cappabianca, P; Colao, A; Del Basso de Caro, ML; Faggiano, A; Ferone, D; Lastoria, S; Lombardi, G; Pivonello, R	1
Nippoldt, TB; Sheehan, MT	1
Góth, M; Hubina, E; Kovács, L; Szabolcs, I	1
Barreca, A; Boghen, M; Dubini, A; Ferrari, C; Fortini, P; Gerevini, G; Paracchi, A; Romano, C	1

Reviews

13 review(s) available for cabergoline and Acromegaly

Article	Year
A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly. Pituitary, 2023, Volume: 26, Issue:1 Topics: Acromegaly; Adult; Cabergoline; Cross-Sectional Studies; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Peptides, Cyclic; Quality of Life	2023
The Role of Dopamine Agonists in Pituitary Adenomas. Endocrinology and metabolism clinics of North America, 2020, Volume: 49, Issue:3 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Human Growth Hormone; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2020
The role of combination medical therapy in acromegaly: hope for the nonresponsive patient. Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:4 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Ligands; Receptors, Somatostatin	2013
[Drug therapy for acromegaly]. Orvosi hetilap, 2013, Sep-29, Volume: 154, Issue:39 Topics: Acromegaly; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Interdisciplinary Communication; Membrane Proteins; Octreotide; Patient Care Team; Peptides, Cyclic; Pituitary Neoplasms; Somatostatin	2013
Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs. Neuroendocrinology, 2016, Volume: 103, Issue:1 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Growth Hormone; Human Growth Hormone; Humans; Somatostatin	2016
Cabergoline use for pituitary tumors and valvular disorders. Endocrinology and metabolism clinics of North America, 2015, Volume: 44, Issue:1 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pituitary Neoplasms; Prolactinoma	2015
The role of combination medical therapy in the treatment of acromegaly. Pituitary, 2017, Volume: 20, Issue:1 Topics: Acromegaly; Cabergoline; Combined Modality Therapy; Ergolines; Humans; Receptors, Somatostatin; Receptors, Somatotropin	2017
Cabergoline in acromegaly. Pituitary, 2017, Volume: 20, Issue:1 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Human Growth Hormone; Humans; Pituitary Neoplasms; Receptors, Somatostatin	2017
Place of cabergoline in acromegaly: a meta-analysis. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:5 Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Data Interpretation, Statistical; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Hormone Antagonists; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Male; Middle Aged; Somatostatin; Treatment Outcome	2011
[Optimization of the medical treatment for acromegaly]. Medicina clinica, 2013, Apr-20, Volume: 140, Issue:8 Topics: Acromegaly; Cabergoline; Combined Modality Therapy; Dopamine Agonists; Dosage Forms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Randomized Controlled Trials as Topic; Receptors, Somatotropin; Somatostatin; Treatment Outcome	2013
Pharmacological approach to the treatment of acromegaly. Neurosurgical focus, 2004, Apr-15, Volume: 16, Issue:4 Topics: Acromegaly; Algorithms; Cabergoline; Dopamine Agonists; Ergolines; Health Care Costs; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Receptors, Somatotropin; Somatostatin; Treatment Outcome	2004
Growth-hormone and prolactin excess. Lancet (London, England), 1998, Oct-31, Volume: 352, Issue:9138 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Hormone Antagonists; Human Growth Hormone; Humans; Hyperprolactinemia; Somatostatin	1998
[Novel pharmacologic therapies in acromegaly]. Orvosi hetilap, 2002, May-12, Volume: 143, Issue:19 Suppl Topics: Acromegaly; Adenoma; Aminoquinolines; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Hormones; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Prolactin; Receptors, Somatotropin; Somatostatin	2002

Trials

11 trial(s) available for cabergoline and Acromegaly

Article	Year
COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018, Volume: 24, Issue:6 Topics: Acromegaly; Adult; Blood Pressure; Cabergoline; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Logistic Models; Male; Middle Aged; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Somatostatin	2018
Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study Endokrynologia Polska, 2019, Volume: 70, Issue:4 Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Longitudinal Studies; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Treatment Outcome	2019
Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clinical endocrinology, 2009, Volume: 71, Issue:1 Topics: Acromegaly; Adult; Aged; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Retrospective Studies; Somatostatin; Treatment Outcome	2009
Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology, 2009, Volume: 90, Issue:1 Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cabergoline; Delayed-Action Preparations; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Humans; Immunohistochemistry; Male; Middle Aged; Octreotide; Prospective Studies; Time Factors; Treatment Outcome	2009
Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology, 2010, Volume: 92, Issue:2 Topics: Acromegaly; Adult; Aged; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Insulin-Like Growth Factor I; Middle Aged; Octreotide; Somatostatin	2010
Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:4 Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Patient Dropouts; Receptors, Somatotropin; United Kingdom	2012
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical endocrinology, 2004, Volume: 61, Issue:2 Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gastrointestinal Agents; Human Growth Hormone; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Male; Maximum Tolerated Dose; Middle Aged; Octreotide; Peptides, Cyclic; Prolactin; Prospective Studies; Somatostatin	2004
Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of endocrinological investigation, 1997, Volume: 20, Issue:9 Topics: Acromegaly; Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactin	1997
Cabergoline in the treatment of acromegaly: a study in 64 patients. The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prospective Studies	1998
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? European journal of endocrinology, 1998, Volume: 139, Issue:5 Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin	1998
Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clinical endocrinology, 1988, Volume: 29, Issue:5 Topics: Acromegaly; Adult; Animals; Cabergoline; Chick Embryo; Dopamine; Dopamine Agents; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactin	1988

Other Studies

60 other study(ies) available for cabergoline and Acromegaly

Article	Year
Quality of life and response to treatment in cats with hypersomatotropism: the owners' point of view. Journal of feline medicine and surgery, 2022, Volume: 24, Issue:8 Topics: Acromegaly; Animals; Cabergoline; Cat Diseases; Cats; Diabetes Mellitus; Quality of Life; Surveys and Questionnaires	2022
Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2022, Volume: 54, Issue:10 Topics: Acromegaly; Cabergoline; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Prolactin; Retrospective Studies	2022
Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors. The Journal of clinical endocrinology and metabolism, 2023, 04-13, Volume: 108, Issue:5 Topics: Acromegaly; Cabergoline; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Prolactin; Receptors, Somatostatin; RNA, Messenger	2023
Pegvisomant in acromegaly: a multicenter real-life study in Argentina. Archives of endocrinology and metabolism, 2019, Aug-22, Volume: 63, Issue:4 Topics: Acromegaly; Adult; Aged; Argentina; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Female; Follow-Up Studies; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Somatostatin; Treatment Outcome; Young Adult	2019
Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary, 2019, Volume: 22, Issue:6 Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Female; Human Growth Hormone; Humans; Interviews as Topic; Male; Middle Aged; Octreotide; Peptides, Cyclic; Personal Satisfaction; Somatostatin; Surveys and Questionnaires	2019
The acromegalic spine: fractures, deformities and spinopelvic balance. Pituitary, 2019, Volume: 22, Issue:6 Topics: Acromegaly; Adult; Aged; Cabergoline; Female; Fractures, Bone; Humans; Insulin-Like Growth Factor I; Lordosis; Lumbar Vertebrae; Lumbosacral Region; Male; Middle Aged; Octreotide; Prospective Studies; Spinal Fractures	2019
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocrine journal, 2020, Feb-28, Volume: 67, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Chemical and Drug Induced Liver Injury; Child; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemia; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Product Surveillance, Postmarketing; Radiotherapy; Receptors, Somatotropin; Somatostatin; Tumor Burden; Young Adult	2020
Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database. Endocrine journal, 2020, Oct-28, Volume: 67, Issue:10 Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Comorbidity; Dopamine Agonists; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperlipidemias; Hypertension; Incidence; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Prevalence; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Somatostatin; Young Adult	2020
Medical Therapy of Acromegaly in Germany 2019 - Data from the German Acromegaly Registry. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2021, Volume: 129, Issue:3 Topics: Acromegaly; Adult; Cabergoline; Dopamine Agonists; Female; Germany; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Peptides, Cyclic; Registries; Retrospective Studies; Somatostatin	2021
Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry. The Journal of clinical endocrinology and metabolism, 2020, 12-01, Volume: 105, Issue:12 Topics: Acromegaly; Adenoma; Adult; Cabergoline; Combined Modality Therapy; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Mexico; Middle Aged; Neurosurgical Procedures; Postoperative Period; Prognosis; Registries; Retrospective Studies; Somatostatin; Treatment Outcome	2020
Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2021, Volume: 129, Issue:9 Topics: Acromegaly; Adult; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Somatostatin; Tertiary Care Centers	2021
Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. The Journal of clinical endocrinology and metabolism, 2017, 08-01, Volume: 102, Issue:8 Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Dwarfism, Pituitary; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Immunoassay; Insulin-Like Growth Factor I; Male; Middle Aged; Neurosurgical Procedures; Somatostatin; Young Adult	2017
The efficacy of medical treatment in patients with acromegaly in clinical practice. Endocrine journal, 2018, Jan-30, Volume: 65, Issue:1 Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Follow-Up Studies; Growth Hormone-Secreting Pituitary Adenoma; Hospitals, University; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Neoplasm Grading; Republic of Korea; Retrospective Studies; Somatostatin; Tumor Burden	2018
Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly. The Journal of clinical endocrinology and metabolism, 2017, 11-01, Volume: 102, Issue:11 Topics: Acromegaly; Adipose Tissue; Adult; Aged; Blood Glucose; Body Composition; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Ergolines; Female; Gonadal Steroid Hormones; Human Growth Hormone; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Lipid Metabolism Disorders; Lipodystrophy; Male; Middle Aged; Peptides, Cyclic; Prednisone; Somatostatin	2017
Large pituitary gland with an expanding lesion in the context of neurofibromatosis 1. BMJ case reports, 2017, Oct-25, Volume: 2017 Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Central Nervous System Cysts; Ergolines; Female; Human Growth Hormone; Humans; Magnetic Resonance Imaging; Neurofibromatosis 1; Pituitary Gland; Pituitary Neoplasms	2017
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report. BMC endocrine disorders, 2018, Jan-24, Volume: 18, Issue:1 Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Hormones; Human Growth Hormone; Humans; Male; Prognosis; Salvage Therapy; Somatostatin	2018
Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clinical endocrinology, 2018, Volume: 88, Issue:6 Topics: Acromegaly; Adult; Aged; Cabergoline; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Receptors, Somatostatin; Retrospective Studies; Young Adult	2018
IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas. Pituitary, 2018, Volume: 21, Issue:4 Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactinoma	2018
Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology. Endokrynologia Polska, 2019, Volume: 70, Issue:1 Topics: Acromegaly; Cabergoline; Endocrinology; Female; Human Growth Hormone; Humans; Male; Pituitary Neoplasms; Poland; Societies, Medical; Somatostatin	2019
Brazilian multicenter study on pegvisomant treatment in acromegaly. Archives of endocrinology and metabolism, 2019, Jul-29, Volume: 63, Issue:4 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Brazil; Cabergoline; Child; Drug Therapy, Combination; Female; Growth Hormone; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Predictive Value of Tests; Receptors, Somatostatin; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult	2019
[Abnormalities of carbohydrate metabolism in acromegaly]. Medicina clinica, 2013, Nov-16, Volume: 141, Issue:10 Topics: Acromegaly; Adult; Aged; Blood Glucose; Body Mass Index; Cabergoline; Combined Modality Therapy; Cranial Irradiation; Cross-Sectional Studies; Ergolines; Female; Glucose; Glycated Hemoglobin; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperglycemia; Hypophysectomy; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Tumor Burden	2013
The role of primary pharmacological therapy in acromegaly. Pituitary, 2014, Volume: 17 Suppl 1 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Human Growth Hormone; Humans; Male; Octreotide; Pituitary Neoplasms; Somatostatin; Young Adult	2014
Acromegaly and pregnancy: a prospective study. European journal of endocrinology, 2014, Volume: 170, Issue:2 Topics: Acromegaly; Adult; Cabergoline; Ergolines; Female; Human Growth Hormone; Humans; Infant, Newborn; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Octreotide; Pregnancy; Pregnancy Complications, Neoplastic; Prospective Studies; Sella Turcica	2014
Cabergoline treatment in acromegaly: cons. Endocrine, 2014, Volume: 46, Issue:2 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Octreotide	2014
Cabergoline treatment in acromegaly: pros. Endocrine, 2014, Volume: 46, Issue:2 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Octreotide; Treatment Outcome	2014
Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis? Boletin de la Asociacion Medica de Puerto Rico, 2014, Volume: 106, Issue:1 Topics: Acanthosis Nigricans; Acromegaly; Adult; Bromocriptine; Cabergoline; Diagnosis, Differential; Ergolines; Female; Gastrointestinal Diseases; Hirsutism; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prognathism; Prolactinoma	2014
[Contemporary options and perspectives in the treatment of acromegaly]. Casopis lekaru ceskych, 2014, Volume: 153, Issue:3 Topics: Acromegaly; Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Radiosurgery; Receptors, Somatotropin; Somatostatin	2014
Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015, Volume: 123, Issue:1 Topics: Acromegaly; Adolescent; Adult; Aged; Bromocriptine; Bulgaria; Cabergoline; Child; Databases, Factual; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Radiotherapy; Remission Induction; Retrospective Studies; Somatostatin	2015
Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors. European journal of endocrinology, 2015, Volume: 172, Issue:6 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Male; Middle Aged; Remission Induction; Somatostatin; Treatment Outcome; Young Adult	2015
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. European journal of endocrinology, 2015, Volume: 173, Issue:5 Topics: Acromegaly; Adolescent; Adult; Antineoplastic Agents; Apnea; Cabergoline; Comorbidity; Ergolines; Female; Follow-Up Studies; Heart Diseases; Human Growth Hormone; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Somatostatin; Young Adult	2015
Patterns of pharmacologic treatment in US patients with acromegaly. Current medical research and opinion, 2016, Volume: 32, Issue:5 Topics: Acromegaly; Adult; Cabergoline; Databases, Factual; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Octreotide; Peptides, Cyclic; Retrospective Studies; Somatostatin	2016
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2016, Volume: 63, Issue:8 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Peptides, Cyclic; Retrospective Studies; Somatostatin	2016
Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study. Journal of endocrinological investigation, 2017, Volume: 40, Issue:5 Topics: Acromegaly; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Octreotide; Prognosis; Prospective Studies; Remission Induction; Withholding Treatment	2017
Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:1 Topics: Acromegaly; Adenoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Cyclophosphamide; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Lymphoma, Non-Hodgkin; Male; Neoplasms, Multiple Primary; Octreotide; Prednisone; Thyroid Neoplasms; Thyroidectomy; Thyroxine; Vincristine	2009
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. European journal of endocrinology, 2008, Volume: 159, Issue:5 Topics: Acromegaly; Adenoma; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Medical Audit; Middle Aged; Pituitary Gland; Prospective Studies; Treatment Outcome	2008
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report. Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:1 Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Ergolines; Facial Bones; Female; Fibrous Dysplasia, Polyostotic; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Pituitary Neoplasms; Skull	2009
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. European journal of endocrinology, 2010, Volume: 162, Issue:4 Topics: Acromegaly; Blood Sedimentation; C-Reactive Protein; Cabergoline; Creatinine; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Electrocardiography; Ergolines; Female; Fibrosis; Glomerular Filtration Rate; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Lung; Lung Diseases; Male; Middle Aged; Respiratory Function Tests; Retroperitoneal Fibrosis; Statistics, Nonparametric	2010
The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2010, Volume: 20, Issue:5 Topics: Acromegaly; Adult; Aged; Blood Glucose; Cabergoline; Cross-Sectional Studies; Ergolines; Female; Human Growth Hormone; Humans; Insulin; Insulin-Like Growth Factor I; Male; Middle Aged; Receptors, Somatotropin	2010
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary, 2011, Volume: 14, Issue:2 Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Time Factors; Young Adult	2011
Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. The Journal of heart valve disease, 2010, Volume: 19, Issue:6 Topics: Acromegaly; Cabergoline; Diuretics; Echocardiography, Doppler, Color; Ergolines; Female; Furosemide; Heart Failure; Hormone Antagonists; Humans; Middle Aged; Severity of Illness Index; Treatment Outcome; Tricuspid Valve Insufficiency	2010
Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary, 2013, Volume: 16, Issue:1 Topics: Acromegaly; Adult; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Retrospective Studies	2013
No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9 Topics: Acromegaly; Adolescent; Adult; Aged; Aortic Valve Insufficiency; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Echocardiography, Doppler; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hypertrophy, Left Ventricular; Longitudinal Studies; Male; Middle Aged; Mitral Valve Insufficiency; Retrospective Studies; Tricuspid Valve Insufficiency; Young Adult	2012
Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary, 2013, Volume: 16, Issue:3 Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Databases, Factual; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Octreotide; Peptides, Cyclic; Retrospective Studies; Somatostatin; United States	2013
Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocrine journal, 2013, Volume: 60, Issue:4 Topics: Acromegaly; Adenoma; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Octreotide; Pituitary Gland; Retrospective Studies; Somatostatin; Tumor Burden; Young Adult	2013
Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary, 2004, Volume: 7, Issue:1 Topics: Acromegaly; Adult; Antineoplastic Agents; Biomarkers; Cabergoline; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Pituitary Gland; Pituitary Neoplasms; Prolactin	2004
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European journal of endocrinology, 2005, Volume: 152, Issue:4 Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactin; Retrospective Studies; Somatostatin	2005
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. American journal of physiology. Endocrinology and metabolism, 2005, Volume: 289, Issue:6 Topics: Acromegaly; Cabergoline; Cell Division; Cell Line, Tumor; Dopamine; Ergolines; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor II; Lung Neoplasms; Peptides, Cyclic; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Somatostatin; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin	2005
Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clinical endocrinology, 2005, Volume: 63, Issue:4 Topics: Acromegaly; Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide	2005
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. Journal of endocrinological investigation, 2006, Volume: 29, Issue:11 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Humans; Somatostatin	2006
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:5 Topics: Acromegaly; Adenoma, Acidophil; Adult; Cabergoline; Cell Proliferation; Cells, Cultured; Delayed-Action Preparations; Ergolines; Human Growth Hormone; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Microscopy, Electron; Octreotide; Pituitary Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Thymidine	2007
Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary, 2008, Volume: 11, Issue:1 Topics: Abdominal Pain; Acromegaly; Adult; Biomarkers; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Libido; Male; Middle Aged; Secondary Prevention; Time Factors; Treatment Outcome	2008
Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary, 2008, Volume: 11, Issue:3 Topics: Acromegaly; Adult; Astrocytoma; Brain Neoplasms; Cabergoline; Cranial Irradiation; Craniotomy; Disease Progression; Ergolines; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Neoplasm Staging; Peptides, Cyclic; Somatostatin; Treatment Outcome; Up-Regulation	2008
Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex. Clinical endocrinology, 1995, Volume: 42, Issue:2 Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Carrier Proteins; Ergolines; Growth Hormone; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Middle Aged; Octreotide	1995
Effect of different dopaminergic agents in the treatment of acromegaly. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:2 Topics: Acromegaly; Adult; Aminoquinolines; Bromocriptine; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Prolactin	1997
Cabergoline treatment of acromegaly: a preliminary dose finding study. Clinical endocrinology, 1997, Volume: 46, Issue:6 Topics: Acromegaly; Adult; Aged; Cabergoline; Depression, Chemical; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactin	1997
Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients. La Clinica terapeutica, 1997, Volume: 148, Issue:12 Topics: Acromegaly; Administration, Oral; Adult; Aged; Cabergoline; Data Interpretation, Statistical; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Hormones; Humans; Injections, Subcutaneous; Male; Middle Aged; Octreotide	1997
Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary, 1999, Volume: 1, Issue:2 Topics: Acromegaly; Adult; Aminoquinolines; Cabergoline; Dopamine Agonists; Drug Synergism; Drug Therapy, Combination; Ergolines; Female; Hormones; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Peptides, Cyclic; Somatostatin; Time Factors	1999
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. Journal of endocrinological investigation, 2001, Volume: 24, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields	2001
In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clinical endocrinology, 2001, Volume: 54, Issue:4 Topics: Acromegaly; Adrenocorticotropic Hormone; Adult; Aminoquinolines; Analysis of Variance; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Growth Hormone; Humans; Immunohistochemistry; Indium Radioisotopes; Insulin-Like Growth Factor I; Iodine Radioisotopes; Luteinizing Hormone; Male; Octreotide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine; Receptors, Somatostatin; Thyrotropin; Tumor Cells, Cultured	2001
Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report. Pituitary, 2000, Volume: 3, Issue:4 Topics: Abdominal Pain; Acromegaly; Adenoma; Adult; Anti-Bacterial Agents; Bile Ducts, Intrahepatic; Bilirubin; Cabergoline; Chemical and Drug Induced Liver Injury; Cholangiopancreatography, Endoscopic Retrograde; Cholelithiasis; Cholesterol; Ergolines; Gram-Negative Bacterial Infections; Hepatectomy; Humans; Insulin-Like Growth Factor I; Liver; Liver Diseases; Male; Octreotide; Pituitary Neoplasms; Postoperative Complications; Sepsis; Surgical Wound Infection	2000